News by subject: TRI

Dilon Technologies Inc. announced today the enrollment of its first patient in the Prospective, Single-Arm, Multi-Center Pivotal Trial for its next generation MarginProbetm 2 product used in real-time margin assessment. "It is thrilling to witness...

Guangzhou Fermion Technology Co., Ltd. (Fermion), a clinical-stage AI-based drug discovery company that specializes in developing drugs for autoimmune diseases and pain management, is pleased to announce the approval of the Investigational New Drug...

Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that the first patient has been...

Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report that the Company has completed its Phase 2a clinical trial (NCT05802173) of TDM-105795 topical solution for Androgenetic Alopecia (AGA)....

iRegene Therapeutics Co., Ltd (iRegene) recently announced that NouvNeu001, the company's first innovative product, has completed the dosing for its first patient at Beijing Hospital, and the patient has also successfully concluded the observation...

Nipocalimab showed clinical efficacy in gMG, a chronic debilitating autoantibody disease where significant unmet patient need exists for efficacious, safe therapies that offer sustained disease control Nipocalimab is the first investigational...

ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced dosing has initiated in the Phase 1/2 first-in-human clinical trial of PRO1107 (NCT06171789)....

Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that in January 2024, the first patient was enrolled and dosed in...

Palatin Technologies, Inc. , a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced database lock for its PL9643 MELODY-1 pivotal Phase 3...

Sirnaomics Ltd. (the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, presented the latest developments...

Acepodia (6976:TT), a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 (??2) T cell platforms to address gaps in cancer care, today announced...

According to American Cancer Society, Cancer causes about 1 in every 6 deaths globally, more than AIDS, tuberculosis, and malaria combined. Today, it is the first or second leading cause of death in most countries around the world. Technological...

Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi, announced 12-month results from the company-sponsored inspIRE study, "Predictors of Success for Pulmonary Vein...

Lumosa Therapeutics (Lumosa; 6535.TWO), together with CHI Memorial have announced the initiation of a Phase 2b clinical trial for LT3001, a groundbreaking drug for treating acute stroke. This new drug combines clot-busting and nerve-protecting...

Inmagene Biopharmaceuticals ("Inmagene" or the "Company"), a clinical stage biotechnology company developing innovative and differentiated therapies...

The 2024 Orthopaedic Research and Education Foundation (OREF) Clinical Research Award was presented to Christopher H. Evans, PhD (Mayo Clinic), Steven C. Ghivizzani, PhD (University of Florida), and Paul D. Robbins, PhD (University of Minnesota), for...

On January 29th, the results of the phase II study on Qilu Pharmaceutical's novel anticancer drug iparomlimab and tuvonralimab (QL1706) were published online in Signal Transduction and Targeted Therapy (Impact Factor=39.3). The study investigated the...

Tyra Biosciences, Inc. , a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that the U.S. Food and Drug...

Nevro Corp. , a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of a consensus statement summarizing recommendations based on...

Madison Wisconsin based Imbed Biosciences, Inc has been awarded a Technology Breakthrough designation for PelashieldAMtm with Premier, Inc. through its Kiindotm pediatric performance group and collaborative. Premier offers Breakthrough Technology...

National Tay-Sachs & Allied Diseases Association (NTSAD), leader in the worldwide fight to treat and cure Tay-Sachs, Canavan, GM1, and Sandhoff diseases, is hosting the first-ever, Externally-Led Patient-Focused Drug Development (EL-PFDD) Meeting for...

Theradaptive, the market leader in targeted regenerative therapeutics, has gained approval from the U.S. Food and Drug Administration (FDA) for their Investigational Device Exemption (IDE) submission to begin enrolling patients into OASIS, their...

Cortex announced today the initiation of its RESOLVE-AF trial (NCT05883631), a study formally launched in late October 2023. The international, multi-center trial will provide clinical evaluation of Cortex's 510(k) cleared Ablamap® System with...

Lindus Health, an "anti-CRO" running radically faster, more reliable clinical trials for life science pioneers, announced the launch of its unified technology, site services and CRO services package for digital therapeutics (DTx) and digital health...

NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that the U.S. Food and Drug...

Graviton Bioscience, a privately held clinical-stage biotechnology company focused on therapies that inhibit Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2), along with...

S4 Medical announced today that its EASY AF FDA study data was published in JACC: Electrophysiology. This prospective, randomized, multicenter, double-blinded study was completed at 12 centers and evaluated esophageal injury related to ablation...

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") , a clinical-stage biotechnology company leveraging its proprietary Diffuspheretm technology to optimize drug delivery for applications with significant unmet need, today announced the...

Results from a recent INC-funded intervention study were published in the American Journal of Clinical Nutrition [1]. The study showed that, for older adults with overweight or obesity, longer-term consumption of mixed nuts significantly improved...

Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced that dosing has begun in Phase IA/IIB clinical trial to study efficacy and safety of BAT6026...

Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to...

On Jan. 30, 2024, PNAS published the research paper titled "Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR T-cell therapy." The paper analyzed results using the fully human B cell maturation antigen...

Artec Biotech, a company in Rosalind Franklin University's Helix 51 Incubator, is developing a potentially promising treatment for glioblastoma multiforme (GBM), a deadly cancer for which patients have few if any therapeutic alternatives....

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced today that the first patient has been dosed with the study drugs in...

The American Physical Therapy Association announces that the U.S. Department of Defense will allow physical therapists to serve as primary care providers for neuromusculoskeletal conditions across all military settings. This designation is based on...

SoniVie, an Israeli company developing a novel, proprietary Therapeutic Intra-Vascular Ultrasound (TIVUSTM) System to treat a variety of hypertensive disorders, announced that on January 8th 2024, the last patient was treated with its Renal Artery...

Published in the European Journal of Preventive Cardiology, the paper demonstrates that polygenic risk score information can be successfully integrated into current general practitioner (GP) clinical practice for the prevention of cardiovascular...

Synergy Spine Solutions, an innovative medical device developer focused on artificial cervical disc replacement, announced today that it has closed on a significant equity financing of $30 million....

SSM Health, a Catholic, not-for-profit and fully-integrated health system serving the comprehensive needs of communities across the Midwest, and Circuit Clinical, a leading integrated research organization, are entering into a strategic partnership...

TriNetX, LLC ("TriNetX"), the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, is proud to announce its participation in the CERTAINTY project. CERTAINTY, short for CEllulaR...

Cadrenal Therapeutics, Inc., , a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet needs in anticoagulation (blood thinning) therapy, cited today a recent peer-reviewed article in the Journal of the...

Mycovia Pharmaceuticals, Inc. ("Mycovia"), an emerging biopharmaceutical company, today announced that its partner Jiangsu Hengrui Pharmaceuticals Co., Ltd ("Hengrui") has...

Neuronoff, Inc., an innovative medical device company focused on simplifying neuromodulation, today announced the successful completion of the first-in-human implant of the Injectrode®. This milestone in chronic pain management involved two study...

Leal Health ("Leal'' or "the Company''), formerly known as Trialjectory, a patient-first, AI-powered treatment platform revolutionizing patient access to cancer care, announced today that it presented a poster at the American Society...

Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura,...

Data supporting the application showed the addition of DARZALEX FASPRO® to lenalidomide, bortezomib and dexamethasone (VRd) induction and consolidation and lenalidomide maintenance therapy reduced the risk of progression or death by 58 percent...

Endogenex, Inc., a clinical stage medical device company dedicated to improving outcomes in patients with Type 2 Diabetes (T2D), announced that the U.S. Food and Drug Administration (FDA) granted an Investigational Device Exemption (IDE) to initiate...

Imagine a day when people can enjoy snacking on foods designed to "re-calibrate" their microbiomes?that vast population of friendly bacteria living in our intestines?in order to promote a healthy immune system and decrease infections or chronic...

ConcertAI, the leader in oncology Real-World Data (RWD) and AI SaaS Solutions and for healthcare and life sciences, today announced Jennifer Rider, ScD, MPH, as the leader of the company's Real-World Evidence Services, focusing on regulatory...

Intera Oncology today announced that Hepatic Artery Infusion (HAI), a liver-directed therapy for...